2017～2019年我院门诊药房心脑血管类理血剂中成药使用情况分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To understand the use of cardio-cerebrovascular blood-regulating agents (hereinafter referred to as "blood-regulating agents") in Huizhou First People′s Hospital from 2017 to 2019,so as to provide reference for clinical rational drug use. Methods The relevant data of "blood-regulating agents" from 2017 to 2019 were extracted from the information HIS system of our hospital,and the defined daily dose (DDD) and drug sum recommended by World Health Organization were used to analyze the annual sales,annual growth rate,medication frequency (DDDs),ranking ratio (B/A) and defined daily cost (DDC) of "blood-regulating agents". Results From 2017 to 2019,the annual sales for"blood regulating agents" in our hospital were 3.4349,3.8983 and 4.2823 million yuan respectively,accounting for 3.35%,3.51% and 3.21% of the total amount of drugs in the hospital,respectively,compared with 2017 and 2018.The growth rates were 13.5% and 9.85% respectively.The annual growth rate of "blood management agents" was 13.50% in 2018 and 9.85% in 2019.The top three sales amount of single variety were Shexiang Baoxin Pills,Xinkeshu Tablets and Naosuantong Capsules.In the order of DDDs,the medication frequency of Xuesaitong Capsules,Quick-acting Heart-saving Pills,Ginkgo Ketone Ester Dropping Pills and Maixuekang Enteric-coated Tablets changed greatly,but the frequency of other drugs was basically stable.The DDC value remained basically stable,and drug prices were stable in the past three years. Conclusion The application of "blood-regulating agent" in our hospital from 2017 to 2019 is ideal,but it is still necessary to strengthen the management of the unreasonable use of drugs to be "safe,effective,economical and reasonable".

Key words： Blood-regulating agents Cardio-cerebrovascular Chinese patent medicine Sales Medication frequency Average daily cost Rational use of drugs

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HONG Huai-zhang
	ZHUO Shao-hua
	QIU Yuan-cong
	HUANG Xin-wei

Cite this article:

HONG Huai-zhang,ZHUO Shao-hua,QIU Yuan-cong, et al. Analysis on the use of cardio-cerebrovascular blood regulating agents in outpatient pharmacy of our hospital from 2017 to 2019[J]. 中国当代医药, 2020, 27(21): 134-138.

URL:

https://dangdaiyiyao.com/EN/ OR https://dangdaiyiyao.com/EN/Y2020/V27/I21/134

[1]	刘云升.活血化瘀药物在心脑血管疾病治疗中的作用分析[J].中西医结合心血管病电子杂志，2016，4（10）：27-28，30.
[2]	周松.活血化瘀法在中医内科中的临床应用分析[J].中医临床研究，2016，8（21）：7-8.
[3]	李喜平，余早勤，刘东.武汉地区34 家医院2011-2013年抗高血压药应用分析[J].中国药房，2015，26（20）：2748-2750.
[4]	郑利光.口腔专科医院2014-2016年门诊中成药使用情况分析[J].中国药业，2018，12（32）：1710-1715.
[5]	陈慧，熊尚全，杨新春.调理气血类中成药防治动脉粥样硬化性心血管疾病临床应用[J].临床心血管杂志，2020，36（2）：97-104.
[6]	中国中西医结合学会心脑血管病专业委员会.麝香保心丸治疗冠心病心绞痛中国专家共识[J].中国中西医结合杂志，2018，38（2）：145-153.
[7]	李俊，俞章平，张云姣.麝香保心丸对老年冠心病介入术后患者血管内皮功能、细胞炎症因子和血脂水平的影响[J].中国老年学杂志，2018，38（23）：5658-5660.
[8]	李五，严晓红，黎磊.稳心颗粒联合麝香保心丸治疗心肌梗死所致心律失常疗效观察[J].现代中西医结合杂志，2017，26（2）：137-140.
[9]	任兰芳，赵显杰.麝香保心丸的临床应用进展[J].中西医结合心脑血管病杂志，2019，17（15）：2291-2292.
[10]	张智慧，杨倩，孙蓉.心可舒片的药理作用及临床应用研究进展[J].中国药物警戒，2016，13（9）：543-546.
[11]	蒋健青，江卫萍，栾献亭.心可舒胶囊联合桂哌齐特治疗不稳定型心绞痛的临床研究[J].现代药物与临床，2019，34（10）：2916-2921.
[12]	尤军.心可舒片与阿托伐他汀钙联合用药方案治疗老年原发性高血压的临床疗效[J].吉林医学，2019，40（1）：110-111.
[13]	李东安，李中平，张慧颖.脑栓通胶囊药效学实验研究[J].中国中医药信息杂志，2003，10（4）：37-39.
[14]	常泽，林景峰，高强，等.脑栓通胶囊治疗急性脑梗死疗效的Meta 分析[J].中西医结合心脑血管病杂志，2019，17（20）：3097-3103.
[15]	向林.脑栓通对急性脑梗死恢复期患者运动功能的影响研究[J].中国药业，2017，26（1）：66-68.